Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has received a consensus rating of “Hold” from the twelve ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $12.83.

Several research firms recently weighed in on ZYNE. Oppenheimer Holdings, Inc. cut shares of Zynerba Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price on shares of Zynerba Pharmaceuticals in a report on Tuesday, August 8th. Jefferies Group LLC lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the stock from $12.00 to $7.00 in a report on Tuesday, August 15th. ValuEngine raised shares of Zynerba Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 13th.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/11/zynerba-pharmaceuticals-inc-zyne-receives-average-rating-of-hold-from-analysts.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors acquired a new position in Zynerba Pharmaceuticals in the 2nd quarter worth $110,000. The Manufacturers Life Insurance Company acquired a new position in Zynerba Pharmaceuticals in the 2nd quarter worth $158,000. FNY Managed Accounts LLC acquired a new position in Zynerba Pharmaceuticals in the 1st quarter worth $180,000. SG Americas Securities LLC acquired a new position in Zynerba Pharmaceuticals in the 1st quarter worth $188,000. Finally, New York State Common Retirement Fund acquired a new position in Zynerba Pharmaceuticals in the 2nd quarter worth $207,000. 34.32% of the stock is owned by hedge funds and other institutional investors.

Shares of Zynerba Pharmaceuticals (NASDAQ ZYNE) traded up 4.22% during trading on Wednesday, reaching $10.37. The company’s stock had a trading volume of 870,793 shares. Zynerba Pharmaceuticals has a 12 month low of $5.42 and a 12 month high of $25.95. The company’s market capitalization is $137.48 million. The company’s 50-day moving average is $7.56 and its 200-day moving average is $7.56.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, analysts forecast that Zynerba Pharmaceuticals will post ($2.42) EPS for the current fiscal year.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.